protein intake optimization glp-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Frontiers | GLP−1 receptor agonists

Weight regain occurs rapidly within months of cessation of treatment, so patients are likely to require chronic medication

Oral GLP-1 receptor agonists are also in the development phase, with preliminary data showing efficacy similar to that of Semaglutide

To view a copy of this licence, visit About this article Cite this article Heni, M., Frhwald, L., Karges, W

Most human studies report a moderate stimulatory effect of GLP-1 on HR with unchanged or with reduced BP only in hypertensive individuals [620,622,640,[644], [645], [646], [647], [648], [649]]

For those who can't afford to contribute right now, please sign up for our free Watchdog Update newsletters, & help the spread word about the Sentinel to your friends, family, neighbors & co-workers